Abstracts

HIV-Associated Kaposi Sarcoma Treated With Chemotherapy and ART in Rural Malawi

Background: HIV-associated Kaposi sarcoma (HIV-KS) is the most common cancer in Malawi. In 2008, the non-governmental organization, Partners In Health, and the Ministry of Health established the Neno Kaposi Sarcoma Clinic (NKSC) to treat HIV-KS in Neno district, one of Malawi’s most rural districts. We hypothesized that a NKSC service delivery model using protocol-guided chemotherapy,…

High Mobility Group Box 1 (HMGB1) and HIV-Associated Kaposi Sarcoma in Africa

Background: The high mobility group box 1 (HMGB1) protein, a host transcriptional regulator that promotes cell proliferation and is actively secreted by senescent cells, is also known to interact with Kaposi’s sarcoma-associated herpesvirus (KSHV) in vitro. HMGB1 binds with KSHV latency-associated nuclear antigen (LANA) and stimulates KSHV “replication and transcriptional activator” (RTA) transactivation, thereby facilitating…

The CXCL12/CXCR4-CXCR7 Pathway, a Trio Implicated in Kaposi Sarcoma Pathogenesis

Background: Lenakap clinical trial (ANRS 154) is a single-arm, multicenter, open label, phase II trial, evaluating the efficacy and safety of lenalidomide in Kaposi’s sarcoma (KS) associated with HIV infection (AIDS-KS) despite an effective antiretroviral (ARV) therapy (NCT01282047). KS is a human herpesvirus 8 (HHV-8)-associated disease. It is known that cytokines are required for the…

Cardiovascular Disease Mortality Among HIV-Infected Persons, New York City, 2001–2012

Background: Cardiovascular disease (CVD) has become more prominent among HIV-infected individuals owing to improved survival, traditional CVD risk factors, and potential effects of antiretroviral therapy (ART). The extent to which CVD mortality rates are changing is unclear but has continued relevance in the context of current ART guidelines. Methods: The population comprised all persons age…

Angiographic Restenosis After PTCA in HIV-Infected Patients: Incidence and Predictors

Background: Patients infected with human immunodeficiency virus (HIV) are at risk of accelerated coronary arteriopathy. With the success of combinded antiretroviral therapy, HIV infection has become a chronic condition and percutaneous coronary intervention (PCI) in HIV-infected patients has become an important treatment option. However, dedicated angiographic follow-up studies examining anti-restenotic efficacy in PCI-treated HIV-infected patients…

PCSK9 Is Elevated in HIV+ Patients and May Mediate HIV-Associated Dyslipidemia

Background: Proprotein convertase subtilisin kexin 9 (PCSK9) is induced by inflammation and leads to elevated levels of LDL cholesterol, increasing cardiovascular risk. Increased PCSK9 might explain the dyslipidemia observed in HIV-infected individuals, which has been previously attributed to HIV medication, HIV disease, and/or chronic inflammation. We aimed to compare PCSK9 levels in HIV-infected individuals and…

Enhanced, Not Inhibited Monocyte Cholesterol Efflux Characterises Untreated HIV

Background: Dyslipidaemia in untreated HIV infection is characterised by reduced high density lipoprotein cholesterol (HDL) and increased risk of cardiovascular disease (CVD). In vitro, HIV impairs monocyte cholesterol efflux (MCE) onto apolipoprotein A1 (ApoA1) via the ATP-binding cassette transporter A1 (ABCA1) potentially explaining lower HDL. We aimed to determine if MCE was inhibited in untreated…